Key Takeaways
- Sanofi is raising the bar for late-stage drug development.
- Recent clinical setbacks are reshaping Sanofi’s R&D strategy.
- Strong Dupixent sales provide stability, but future growth depends on pipeline renewal.
Sanofi is undertaking a comprehensive review of its late-stage drug pipeline as new Chief Executive Officer Belén Garijo looks to strengthen the company’s research and development strategy following a series of clinical setbacks. The move marks one of the first major strategic initiatives under the new leadership and signals a shift toward a more disciplined approach to drug development, with greater emphasis on scientific differentiation, commercial potential, and long-term value creation.
The review comes at a pivotal time for the French pharmaceutical giant, which is working to build its next generation of blockbuster medicines while preparing for the eventual loss of exclusivity for Dupixent, its flagship treatment for inflammatory diseases. Although the drug continues to drive strong revenue growth, Sanofi is focused on ensuring that its pipeline can support sustainable growth over the next decade.
Pipeline Review Comes After Multiple Drug Development Setbacks
Sanofi’s decision to reassess its late-stage portfolio follows a series of disappointing clinical trial outcomes that have reshaped its research priorities. One of the most notable setbacks was the discontinuation of amlitelimab for atopic dermatitis after the company determined the treatment no longer met its expectations for future development. The therapy had once been considered a potential blockbuster with projected annual sales running into billions of dollars. Earlier, the company had also halted its development for asthma after unfavorable Phase II trial results.
The challenges have extended beyond a single program. Balinatunfib failed to achieve its primary endpoint in a mid-stage psoriasis study, while itepekimab, an IL-33 antibody being co-developed with Regeneron, missed one of its Phase III endpoints in chronic obstructive pulmonary disease (COPD). These setbacks have reduced the number of late-stage assets expected to contribute to Sanofi’s future growth and intensified the company’s focus on strengthening its research portfolio.
Rather than advancing drug candidates simply because they have reached Phase III development, Sanofi is now evaluating each program based on its scientific profile, probability of success, and commercial relevance. The company believes that applying stricter criteria earlier in the development process will improve the quality of its pipeline and enable more efficient allocation of research investments.
New Leadership Prioritizes Quality, Innovation, and Strategic Discipline
Under Belén Garijo’s leadership, Sanofi is placing greater emphasis on quality over quantity within its research portfolio. The company is seeking to concentrate resources on programs that demonstrate meaningful clinical differentiation and have the potential to address significant unmet medical needs while delivering sustainable commercial returns.
The strategy also includes broader changes to research governance and investment decisions. By integrating financial oversight more closely with research and business development, Sanofi aims to improve decision-making across the organization and identify opportunities for external innovation through licensing agreements, strategic partnerships, and acquisitions.
Industry analysts believe the review reflects a long-term transformation rather than a temporary response to recent failures. While discontinuing late-stage assets can be costly in the short term, removing weaker programs allows companies to redirect capital toward higher-potential medicines and emerging technologies. For Sanofi, the review is expected to create greater flexibility to pursue innovative therapies across its key focus areas while reducing the risk of investing heavily in programs with limited chances of success.
The Belén Garijo-led company CEO has also acknowledged that strengthening its pipeline will require continued investment in research and development. Management has indicated that R&D spending will remain a priority even as Sanofi adopts a more selective approach to advancing clinical candidates.
Strong Commercial Performance Provides Stability During Transition
Despite the ongoing pipeline restructuring, Sanofi’s commercial business continues to deliver solid financial performance. The company recently reported stronger-than-expected quarterly results, supported primarily by continued demand for Dupixent, which remains one of the world’s leading treatments for eczema, asthma, and several other immune-mediated diseases. The strong performance prompted Sanofi to raise its full-year sales outlook, underscoring the resilience of its existing product portfolio.
However, management has also recognized that relying heavily on a single blockbuster therapy presents long-term challenges. As Dupixent approaches future patent expiry, investors and analysts are closely watching how effectively Sanofi can develop the next wave of innovative medicines capable of sustaining revenue growth.
Recent impairment charges linked to discontinued clinical programs highlight the financial impact of the company’s portfolio reset. Nevertheless, the leadership team views these decisions as necessary to improve long-term research productivity and increase the likelihood of bringing more differentiated therapies to market.
Going forward, Sanofi’s strategy is expected to center on disciplined portfolio management, stronger scientific evaluation, and targeted investments in high-potential assets. While the review may create near-term uncertainty around certain development programs, it reflects the company’s broader commitment to building a more resilient and competitive pipeline. By prioritizing innovation with clear clinical and commercial value, Sanofi aims to strengthen its position in the global pharmaceutical market and lay the foundation for sustainable growth beyond the Dupixent era.
Check out CIO Women Magazine for the latest updates in business, technology, and innovation.
